CoChat

Intrapatient Cetuximab Dose Escalation in Metastatic Colorectal Cancer According to the Grade of Early Skin Reactions: The Randomized EVEREST Study

Open access
Van Cutsem, Eric, Tejpar, Sabine, Vanbeckevoort, Dirk, Peeters, Marc, Humblet, Yves, Gelderblom, Hans, Vermorken, Jan B., Viret, Frederic, Glimelius, Bengt, Gallerani, Elisa, Hendlisz, Alain, Cats, Annemieke, Moehler, Markus, Sagaert, Xavier, Vlassak, Soetkin, Schlichting, Michael, Ciardiello, Fortunato · 2012 · Journal of Clinical Oncology
Cited by 132

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Abstract

Purpose: Skin toxicity in patients receiving cetuximab has been associated positively with clinical outcome in several tumor types. This study investigated the effect of cetuximab dose escalation in patients with irinotecan-refractory metastatic colorectal cancer who had developed no or mild skin reactions after 21 days of treatment at the standard dose. This article reports clinical and pharmacokinetic (PK) data. Patients and Methods: After 21 days of standard-dose cetuximab (400 mg/m 2 initial dose, then 250 mg/m 2 per week) plus irinotecan, patients with ≤ grade 1 skin reactions were randomly assigned to standard-dose (group A) or dose-escalated (to 500 mg/m 2 per week; group B) cetuximab. Patients with ≥ grade 2 skin reactions continued on standard-dose cetuximab plus irinotecan (group C). Results: The intent-to-treat population comprised 157 patients. PK profiles reflected the dose increase and were predictable across the dose range investigated. Weekly cetuximab doses of up to 500 mg/m 2 were well tolerated, and grade 3 and 4 adverse events were generally comparable between treatment groups. Dose escalation (n = 44) was associated with an increase in skin reactions ≥ grade 2 compared with standard (n = 45) dosing (59% v 38%, respectively). Dose escalation, compared with standard dosing, showed some evidence for improved response rate (30% v 16%, respectively) and disease control rate (70% v 58%, respectively) but no indication of benefit in relation to overall survival. In an exploratory analysis, dose escalation seemed to increase response rate compared with standard dosing in patients with KRAS wild-type but not KRAS mutant tumors. Conclusion: Cetuximab serum concentrations increased predictably with dose. Higher dose levels were well tolerated. The possible indication for improved efficacy in the dose-escalation group warrants further investigation.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.2011.40.9243

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 6 references

Cited by

See all 132

Metadata

Authors
Van Cutsem, E., Tejpar, S., Vanbeckevoort, D., Peeters, M., Humblet, Y., Gelderblom, H., Vermorken, J. B., Viret, F., Glimelius, B., Gallerani, E., Hendlisz, A., Cats, A., Moehler, M., Sagaert, X., Vlassak, S., Schlichting, M., & Ciardiello, F.
Venue
Journal of Clinical Oncology
Published
2012-08-10
Volume
30
Issue
23
Pages
2861-2868
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W2107692859
Cited by
132
References
6
FWCI
7.81
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Intrapatient Cetuximab Dose Escalation in Metastatic Colorectal Cancer According to the Grade of Early Skin Reactions: The Randomized EVEREST Study. https://app.cochat.ai/papers/10.1200/jco.2011.40.9243
The paper
Van Cutsem, E., Tejpar, S., Vanbeckevoort, D., Peeters, M., Humblet, Y., Gelderblom, H., Vermorken, J. B., Viret, F., Glimelius, B., Gallerani, E., Hendlisz, A., Cats, A., Moehler, M., Sagaert, X., Vlassak, S., Schlichting, M., & Ciardiello, F. (2012). Intrapatient Cetuximab Dose Escalation in Metastatic Colorectal Cancer According to the Grade of Early Skin Reactions: The Randomized EVEREST Study. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2011.40.9243

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.